# Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

> **NCT02482311** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 92 (actual)

## Conditions studied

- Ovarian Cancer, TNBC, SCLC, Other Solid Tumours

## Interventions

- **DRUG:** AZD 1775

## Key facts

- **NCT ID:** NCT02482311
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-01
- **Primary completion:** 2018-01-25
- **Final completion:** 2019-08-22
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02482311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02482311, "Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02482311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*